Pfizer CEO Albert Bourla has revealed details of a new weight loss drug with a dual action mechanism targeting metabolic pathways for efficient fat oxidation and appetite regulation. Early trials show promise in safety and efficacy, potentially transforming obesity treatment.
Pfizer, known for its life-saving medications and vaccines, currently faces market pessimism despite strong financial health, a diverse portfolio, and strategic acquisitions. Its undervaluation may present a rare investment opportunity.
Explore investing in high-yield dividend stocks near their 52-week lows. Learn about Pfizer, Bristol-Myers Squibb, and Gilead Sciences, prime candidates for a buy-and-hold strategy with substantial dividend yields.
